NASDAQ:SGTX

Sigilon Therapeutics - SGTX Stock Forecast, Price & News

$0.72

-0.01 (-1.38%)

(As of 02/1/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.71
▼
$0.74
50-Day Range: $0.29
▼
$0.74
52-Week Range: $0.29
▼
$1.90

Volume: 29,503 shs
Average Volume: 622,372 shs
Market Capitalization: $23.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Institutional Ownership

Sigilon Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 738.8% Upside
$6.00 Price Target
Short Interest: Healthy
0.73% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.60) to ($1.46) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

127th out of 1,053 stocks

Pharmaceutical Preparations Industry

53rd out of 519 stocks

3.5

Analyst's Opinion

Consensus Rating
Sigilon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Sigilon Therapeutics has a forecasted upside of 738.8% from its current price of $0.72.
Amount of Analyst Coverage
Sigilon Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.73% of the float of Sigilon Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Sigilon Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sigilon Therapeutics has recently decreased by 5.05%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Sigilon Therapeutics does not currently pay a dividend.
Dividend Growth
Sigilon Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SGTX.

3.8

News and Social Media Coverage

News Sentiment
Sigilon Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.
Search Interest
6 people have searched for SGTX on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added Sigilon Therapeutics to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sigilon Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.20% of the stock of Sigilon Therapeutics is held by insiders.
Percentage Held by Institutions
52.20% of the stock of Sigilon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Sigilon Therapeutics are expected to grow in the coming year, from ($1.60) to ($1.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sigilon Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sigilon Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sigilon Therapeutics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sigilon Therapeutics (NASDAQ:SGTX) Stock

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive SGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SGTX Stock News Headlines

January 19, 2023 | msn.com

Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

November 12, 2022 | finance.yahoo.com

Sigilon Therapeutics Third Quarter 2022 Earnings: Beats Expectations

February 2, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.

November 10, 2022 | finanznachrichten.de

Sigilon Therapeutics, Inc.: Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

November 10, 2022 | finance.yahoo.com

Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

November 10, 2022 | finance.yahoo.com

Sigilon Therapeutics, Inc. (SGTX) Reports Q3 Loss, Tops Revenue Estimates

September 24, 2022 | finance.yahoo.com

Delix Therapeutics Expands World-Class Team with First Head of R&D

September 23, 2022 | benzinga.com

Aspect Biosystems Appoints Three New Board Members

February 2, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

August 5, 2022 | finance.yahoo.com

Sigilon Therapeutics, Inc. (SGTX) Reports Q2 Loss, Tops Revenue Estimates

August 4, 2022 | finance.yahoo.com

Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

May 14, 2022 | seekingalpha.com

Sigilon Therapeutics GAAP EPS of -$0.43, revenue of $3.17M

May 13, 2022 | finance.yahoo.com

Sigilon Therapeutics Reports First Quarter 2022 Financial Results And Business Highlights

May 13, 2022 | finance.yahoo.com

Sigilon Therapeutics, Inc. (SGTX) Reports Q1 Loss, Tops Revenue Estimates

April 7, 2022 | finance.yahoo.com

Sigilon Therapeutics to Present at the Needham Healthcare Conference

March 16, 2022 | benzinga.com

Looking Into Sigilon Therapeutics's Return On Capital Employed

March 14, 2022 | finance.yahoo.com

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

March 14, 2022 | finance.yahoo.com

Sigilon Therapeutics, Inc. (SGTX) Reports Q4 Loss, Misses Revenue Estimates

March 8, 2022 | finance.yahoo.com

Sigilon Therapeutics to Present at the Barclays Global Healthcare Conference

March 3, 2022 | finance.yahoo.com

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon Therapeutics

March 2, 2022 | finance.yahoo.com

4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry

February 18, 2022 | bizjournals.com

Yumanity cuts staff by 60%, considers a sale

February 7, 2022 | finance.yahoo.com

Bears are Losing Control Over Sigilon Therapeutics, Inc. (SGTX), Here's Why It's a 'Buy' Now

January 31, 2022 | finance.yahoo.com

Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and MPS-6

January 14, 2022 | nasdaq.com

Sigilon Therapeutics Inc Shares Fall 4.4% Below Previous 52-Week Low - Market Mover

December 14, 2021 | finance.yahoo.com

Sigilon Therapeutics to lay off 40 employees

December 14, 2021 | markets.businessinsider.com

The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SGTX Company Calendar

Last Earnings: 11/10/2022
Today: 2/01/2023
Next Earnings (Estimated): 3/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SGTX
CUSIP: N/A
CIK: 1821323
Web: sigilon.com
Phone: 617-336-7540
Fax: N/A
Employees: 66
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +738.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-77,310,000.00
Net Margins: -444.44%
Pretax Margin: -444.43%
Return on Equity: -91.82%
Return on Assets: -46.23%

Debt

Debt-to-Equity Ratio: 0.31
Current Ratio: 2.64
Quick Ratio: 2.64

Sales & Book Value

Annual Sales: $9.60 million
Price / Sales: 2.42
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.39 per share
Price / Book: 0.30

Miscellaneous

Outstanding Shares: 32,460,000
Free Float: 31,094,000
Market Cap: $23.22 million
Optionable: Not Optionable
Beta: 0.14

Key Executives

Dr. Rogerio Vivaldi Coelho M.B.A. (Age 59)
M.D., MBA, Pres, CEO & Director
Comp: $745.9k

Dr. Daniel G. Anderson Ph.D. (Age 53)
Co-Founder & Member of Scientific Advisory Board
Comp: $46.92k

Mr. Philip Ashton-Rickardt Ph.D. (Age 59)
Chief Scientific Officer
Comp: $445.44k

Dr. May Orfali M.B.A. (Age 55)
M.D., Exec. VP & Chief Medical Officer
Comp: $536.67k

Dr. Robert S. Langer Jr. (Age 74)
Ph.D., Sc.D., SCD, Co-Founder & Member of Scientific Advisory Board

Dr. Omid Veiseh Ph.D.
Co-Founder

Dr. José Oberholzer M.D.
Co-Founder

Dr. Arturo Vegas Ph.D.
Co-Founder

Mr. Josias Fantato De Pontes M.B.A. (Age 57)
Acting CFO, Sr. VP, Principal Accounting Officer & Treasurer

Mr. Robert Windsor Jr.
J.D., VP & Head of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions

SGTX Stock - Frequently Asked Questions

Should I buy or sell Sigilon Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sigilon Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SGTX shares.
View SGTX analyst ratings or view top-rated stocks.
What is Sigilon Therapeutics' stock price forecast for 2023?: 1 Wall Street research analysts have issued twelve-month price targets for Sigilon Therapeutics' stock. Their SGTX share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next year. This suggests a possible upside of 727.9% from the stock's current price.
View analysts price targets for SGTX or view top-rated stocks among Wall Street analysts.
How have SGTX shares performed in 2023?: Sigilon Therapeutics' stock was trading at $0.35 at the beginning of 2023. Since then, SGTX stock has increased by 107.1% and is now trading at $0.7247.
View the best growth stocks for 2023 here.
When is Sigilon Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our SGTX earnings forecast.
How were Sigilon Therapeutics' earnings last quarter?: Sigilon Therapeutics, Inc. (NASDAQ:SGTX) issued its earnings results on Thursday, November, 10th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.16. The business had revenue of $4.25 million for the quarter, compared to the consensus estimate of $2.45 million. Sigilon Therapeutics had a negative trailing twelve-month return on equity of 91.82% and a negative net margin of 444.44%.

When did Sigilon Therapeutics IPO?: (SGTX) raised $101 million in an IPO on Friday, December 4th 2020. The company issued 5,600,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity acted as the underwriters for the IPO.
What is Sigilon Therapeutics' stock symbol?: Sigilon Therapeutics trades on the NASDAQ under the ticker symbol "SGTX."
Who are Sigilon Therapeutics' major shareholders?: Sigilon Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel Griffith Anderson and Lilly & Co Eli.
View institutional ownership trends.
How do I buy shares of Sigilon Therapeutics?: Shares of SGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sigilon Therapeutics' stock price today?: One share of SGTX stock can currently be purchased for approximately $0.72.
How much money does Sigilon Therapeutics make?: Sigilon Therapeutics (NASDAQ:SGTX) has a market capitalization of $23.52 million and generates $9.60 million in revenue each year. The company earns $-77,310,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.
How can I contact Sigilon Therapeutics?: The official website for the company is sigilon.com. The company can be reached via phone at 617-336-7540 or via email at robert.windsor@sigilon.com.

This page (NASDAQ:SGTX) was last updated on 2/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Sigilon Therapeutics - SGTX Stock Forecast, Price & News

Sigilon Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Sigilon Therapeutics (NASDAQ:SGTX) Stock

SGTX Stock News Headlines

SGTX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SGTX Stock - Frequently Asked Questions

Overall MarketRank^™